Ivette Essers1, Sofia Ramiro2, Carmen Stolwijk2, Marc Blaauw3, Robert Landewé2, Désirée van der Heijde3, Filip Van den Bosch3, Maxime Dougados3, Astrid van Tubergen2. 1. Department of Medicine, Maastricht University Medical Center, School for Public Health and Primary Care (CAPHRI), University of Maastricht, Maastricht, Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, The Netherlands, Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Department of Medicine, Catherina Hospital, Eindhoven, Department of Rheumatology, Atrium Medical Center, Heerlen, Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, Ghent University Hospital and University of Ghent, Ghent, Belgium and Rheumatology Department, Paris-Descartes University, Cochin Hospital, Paris, France. Department of Medicine, Maastricht University Medical Center, School for Public Health and Primary Care (CAPHRI), University of Maastricht, Maastricht, Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, The Netherlands, Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Department of Medicine, Catherina Hospital, Eindhoven, Department of Rheumatology, Atrium Medical Center, Heerlen, Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, Ghent University Hospital and University of Ghent, Ghent, Belgium and Rheumatology Department, Paris-Descartes University, Cochin Hospital, Paris, France. ivette.essers@maastrichtuniversity.nl. 2. Department of Medicine, Maastricht University Medical Center, School for Public Health and Primary Care (CAPHRI), University of Maastricht, Maastricht, Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, The Netherlands, Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Department of Medicine, Catherina Hospital, Eindhoven, Department of Rheumatology, Atrium Medical Center, Heerlen, Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, Ghent University Hospital and University of Ghent, Ghent, Belgium and Rheumatology Department, Paris-Descartes University, Cochin Hospital, Paris, France. Department of Medicine, Maastricht University Medical Center, School for Public Health and Primary Care (CAPHRI), University of Maastricht, Maastricht, Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, The Netherlands, Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Department of Medicine, Catherina Hospital, Eindhoven, Department of Rheumatology, Atrium Medical Center, Heerlen, Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, Ghent University Hospital and University of Ghent, Ghent, Belgium and Rheumatology Department, Paris-Descartes University, Cochin Hospital, Paris, France. 3. Department of Medicine, Maastricht University Medical Center, School for Public Health and Primary Care (CAPHRI), University of Maastricht, Maastricht, Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, The Netherlands, Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Department of Medicine, Catherina Hospital, Eindhoven, Department of Rheumatology, Atrium Medical Center, Heerlen, Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Department of Rheumatology, Ghent University Hospital and University of Ghent, Ghent, Belgium and Rheumatology Department, Paris-Descartes University, Cochin Hospital, Paris, France.
Abstract
OBJECTIVE: The aim of this study was to identify characteristics associated with the presence and development of extra-articular manifestations (EAMs) in a prevalence cohort of patients with AS. METHODS: Twelve-year follow-up data from the Outcome in Ankylosing Spondylitis International Study (OASIS) were used. In addition, medical charts were checked for the presence of acute anterior uveitis (AAU), IBD and psoriasis. Demographic, clinical and radiographic characteristics associated with the presence of (any) EAM at baseline or new development during follow-up were identified. RESULTS: Two hundred and sixteen patients were included [mean age 43.6 years (s.d. 12.7), 154 (71%) men, mean symptom duration 20.5 years (s.d. 11.7), mean follow-up 8.3 years (s.d. 4.3)]. At baseline, 39 (18%) patients had AAU, 15 (7%) had IBD and 9 (4%) had psoriasis. The history of AAU was univariably associated with increased age [odds ratio (OR) 1.04 (95% CI 1.01, 1.07)], longer symptom duration [OR 1.05 (95% CI 1.02, 1.08)] and more radiographic damage [OR 1.02 (95% CI 1.00, 1.04)]. The history of psoriasis was associated with greater age [OR 1.05 (95% CI 1.00, 1.11)] and lower CRP [OR 0.77 (95% CI 0.59, 1.00)]. At follow-up, 27 patients developed a new EAM. Newly developed IBD was associated with a higher time-varying AS Disease Activity Score [hazard ratio (HR) 2.80 (95% CI 1.43, 5.52)], worse physical function [HR 1.40 (95% CI 1.09, 1.80)] and worse patient global well-being [HR 1.46 (95% CI 1.10, 1.93)]. Newly developed AAU was associated with an elevated time-varying CRP [HR 1.02 (95% CI 1.01, 1.04)]. CONCLUSION: Development of EAMs was infrequent in this cohort, despite relatively long follow-up. In particular, markers of disease activity were associated with the development of IBD.
OBJECTIVE: The aim of this study was to identify characteristics associated with the presence and development of extra-articular manifestations (EAMs) in a prevalence cohort of patients with AS. METHODS: Twelve-year follow-up data from the Outcome in Ankylosing Spondylitis International Study (OASIS) were used. In addition, medical charts were checked for the presence of acute anterior uveitis (AAU), IBD and psoriasis. Demographic, clinical and radiographic characteristics associated with the presence of (any) EAM at baseline or new development during follow-up were identified. RESULTS: Two hundred and sixteen patients were included [mean age 43.6 years (s.d. 12.7), 154 (71%) men, mean symptom duration 20.5 years (s.d. 11.7), mean follow-up 8.3 years (s.d. 4.3)]. At baseline, 39 (18%) patients had AAU, 15 (7%) had IBD and 9 (4%) had psoriasis. The history of AAU was univariably associated with increased age [odds ratio (OR) 1.04 (95% CI 1.01, 1.07)], longer symptom duration [OR 1.05 (95% CI 1.02, 1.08)] and more radiographic damage [OR 1.02 (95% CI 1.00, 1.04)]. The history of psoriasis was associated with greater age [OR 1.05 (95% CI 1.00, 1.11)] and lower CRP [OR 0.77 (95% CI 0.59, 1.00)]. At follow-up, 27 patients developed a new EAM. Newly developed IBD was associated with a higher time-varying AS Disease Activity Score [hazard ratio (HR) 2.80 (95% CI 1.43, 5.52)], worse physical function [HR 1.40 (95% CI 1.09, 1.80)] and worse patient global well-being [HR 1.46 (95% CI 1.10, 1.93)]. Newly developed AAU was associated with an elevated time-varying CRP [HR 1.02 (95% CI 1.01, 1.04)]. CONCLUSION: Development of EAMs was infrequent in this cohort, despite relatively long follow-up. In particular, markers of disease activity were associated with the development of IBD.
Authors: U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking Journal: Z Rheumatol Date: 2019-12 Impact factor: 1.372
Authors: Janneke J de Winter; Leonieke J van Mens; Désirée van der Heijde; Robert Landewé; Dominique L Baeten Journal: Arthritis Res Ther Date: 2016-09-01 Impact factor: 5.156
Authors: Karin Bengtsson; Helena Forsblad-d'Elia; Anna Deminger; Eva Klingberg; Mats Dehlin; Sofia Exarchou; Ulf Lindström; Johan Askling; Lennart T H Jacobsson Journal: Rheumatology (Oxford) Date: 2021-06-18 Impact factor: 7.580